Divisadero Street Capital Management LP Takes $3.31 Million Position in Xeris Biopharma Holdings, Inc. $XERS

Divisadero Street Capital Management LP bought a new stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 406,334 shares of the company’s stock, valued at approximately $3,308,000. Divisadero Street Capital Management LP owned 0.24% of Xeris Biopharma as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also added to or reduced their stakes in XERS. Geode Capital Management LLC raised its holdings in Xeris Biopharma by 7.2% in the 2nd quarter. Geode Capital Management LLC now owns 3,650,688 shares of the company’s stock valued at $17,052,000 after acquiring an additional 244,862 shares in the last quarter. Qube Research & Technologies Ltd grew its holdings in shares of Xeris Biopharma by 67.5% during the 2nd quarter. Qube Research & Technologies Ltd now owns 3,089,771 shares of the company’s stock worth $14,429,000 after purchasing an additional 1,245,188 shares in the last quarter. Goldman Sachs Group Inc. increased its position in shares of Xeris Biopharma by 75.4% during the first quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company’s stock valued at $15,317,000 after purchasing an additional 1,199,435 shares during the period. Millennium Management LLC increased its position in shares of Xeris Biopharma by 19.0% during the first quarter. Millennium Management LLC now owns 2,317,972 shares of the company’s stock valued at $12,726,000 after purchasing an additional 369,420 shares during the period. Finally, Legal & General Group Plc raised its stake in shares of Xeris Biopharma by 27.8% in the second quarter. Legal & General Group Plc now owns 1,804,203 shares of the company’s stock valued at $8,426,000 after purchasing an additional 392,589 shares in the last quarter. 42.75% of the stock is owned by institutional investors and hedge funds.

Xeris Biopharma Stock Down 0.4%

NASDAQ XERS opened at $5.46 on Monday. The stock has a market capitalization of $941.47 million, a P/E ratio of -545.45 and a beta of 0.61. Xeris Biopharma Holdings, Inc. has a 52 week low of $3.81 and a 52 week high of $10.08. The company has a debt-to-equity ratio of 16.10, a quick ratio of 1.57 and a current ratio of 2.19. The stock has a fifty day moving average of $6.91 and a 200-day moving average of $7.51.

Xeris Biopharma (NASDAQ:XERS) last issued its quarterly earnings results on Monday, March 2nd. The company reported $0.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.03 by $0.03. The business had revenue of $85.81 million for the quarter, compared to analyst estimates of $86.00 million. Xeris Biopharma had a negative return on equity of 5.33% and a net margin of 0.19%. On average, equities research analysts forecast that Xeris Biopharma Holdings, Inc. will post -0.41 EPS for the current year.

Insider Buying and Selling at Xeris Biopharma

In other news, insider John Patrick Shannon, Jr. sold 24,907 shares of the firm’s stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $7.08, for a total value of $176,341.56. Following the transaction, the insider owned 2,705,346 shares of the company’s stock, valued at approximately $19,153,849.68. This trade represents a 0.91% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director John Johnson sold 135,400 shares of the business’s stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $7.22, for a total transaction of $977,588.00. Following the sale, the director directly owned 698,083 shares of the company’s stock, valued at approximately $5,040,159.26. This trade represents a 16.25% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 225,308 shares of company stock valued at $1,626,103. 4.56% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several brokerages recently commented on XERS. Wall Street Zen raised Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a research report on Saturday, March 7th. Weiss Ratings upgraded shares of Xeris Biopharma from a “sell (d-)” rating to a “hold (c-)” rating in a research note on Wednesday, March 4th. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of Xeris Biopharma in a report on Monday, March 2nd. Finally, Barclays started coverage on shares of Xeris Biopharma in a research report on Monday, December 8th. They set an “overweight” rating and a $9.00 target price on the stock. Four investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $10.80.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.